Reaction
Injection Site Scar reporting signals
As of the last recalculation, Injection Site Scar appears in 2,781 FAERS reports alongside 41 co-occurring drug terms. The strongest observed disproportionality signal is INTERFERON BETA-1B (PRR 59.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Interferon Beta-1B | 145 | 59.7 | 60.1 |
| Pegvaliase-Pqpz | 42 | 38.8 | 39.0 |
| Glatiramer Acetate | 237 | 32.4 | 32.5 |
| Asfotase Alfa | 25 | 18.8 | 18.9 |
| Interferon Beta-1A | 407 | 18.3 | 18.3 |
| Lanreotide Acetate | 19 | 18.3 | 18.3 |
| Fremanezumab-Vfrm | 25 | 16.4 | 16.5 |
| Octreotide Acetate | 50 | 12.4 | 12.4 |
| Peginterferon Beta-1A | 19 | 10.9 | 10.9 |
| Anakinra | 22 | 10.0 | 10.0 |
| Naltrexone | 38 | 9.3 | 9.4 |
| Insulin Lispro | 130 | 7.3 | 7.3 |
| Teduglutide | 12 | 6.7 | 6.7 |
| Insulin Glulisine | 9 | 6.6 | 6.6 |
| Galcanezumab-Gnlm | 26 | 6.2 | 6.2 |
| Cabotegravir | 6 | 5.6 | 5.6 |
| Insulin Human | 29 | 5.5 | 5.5 |
| Insulin Degludec | 17 | 5.4 | 5.5 |
| Dulaglutide | 62 | 5.3 | 5.3 |
| Epinephrine | 42 | 4.9 | 4.9 |
| Abaloparatide | 19 | 4.9 | 4.9 |
| Fulvestrant | 20 | 4.6 | 4.6 |
| Insulin Glargine | 130 | 4.1 | 4.1 |
| Tirzepatide | 70 | 3.3 | 3.3 |
| Alirocumab | 11 | 3.3 | 3.3 |
| Dalfampridine | 31 | 3.3 | 3.3 |
| Ixekizumab | 16 | 3.2 | 3.3 |
| Erenumab-Aooe | 21 | 2.9 | 2.9 |
| Diclofenac Potassium | 4 | 2.8 | 2.8 |
| Onabotulinumtoxina | 28 | 2.7 | 2.7 |
| Paliperidone Palmitate | 11 | 2.6 | 2.6 |
| Teriparatide | 38 | 2.5 | 2.5 |
| Dupilumab | 154 | 2.5 | 2.5 |
| Botulinum Toxin Type A | 4 | 2.4 | 2.4 |
| Exenatide | 16 | 2.3 | 2.3 |
| Sarilumab | 8 | 2.3 | 2.3 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 3 | 2.2 | 2.2 |
| Ofatumumab | 9 | 2.0 | 2.0 |
| Evolocumab | 40 | 1.9 | 1.9 |
| Somatropin | 18 | 1.8 | 1.8 |
| Buprenorphine | 22 | 1.8 | 1.8 |